SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 100.32 |
| Enterprise Value ($M) | 91.76 |
| Book Value ($M) | 26.27 |
| Book Value / Share | 0.70 |
| Price / Book | 3.82 |
| NCAV ($M) | 23.11 |
| NCAV / Share | 0.62 |
| Price / NCAV | 4.34 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.06 |
| Return on Assets (ROA) | -1.21 |
| Return on Equity (ROE) | -1.98 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.57 |
| Current Ratio | 4.57 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 31.55 |
| Assets | 34.72 |
| Liabilities | 8.44 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.01 |
| Operating Income | -31.70 |
| Net Income | -29.87 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -21.23 |
| Cash from Investing | -8.13 |
| Cash from Financing | 28.51 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Highbridge Capital Management Llc | 6.80 | ||
| 13G/A | Szalay Aladar | 9.90 | -18.44 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 21,563 | 101,563 | 21.23 | |
| 20,938 | 149,045 | 14.05 | |
| 17,396 | 57,226 | 30.40 | |
| 13,435 | 37,958 | 35.39 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GLSI – Greenwich LifeSciences, Inc. | GLTO – Galecto, Inc. |
| GLYC – GlycoMimetics, Inc. | GNPX – Genprex, Inc. |
| GOVX – GeoVax Labs, Inc. |
Financial data and stock pages provided by
Fintel.io